BiotechTube
NLS Pharmaceutics

NLS Pharmaceutics

NLSP
Zug, Switzerland· Est.
nlspharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

NLS Pharmaceutics is a clinical-stage biotech focused on developing improved therapeutics for CNS disorders, particularly narcolepsy. Its core strategy involves the repurposing and reformulation of known pharmacologic agents to enhance efficacy, duration, and tolerability. The company's lead asset, Mazindol ER (NLS-4/Quilience®), has demonstrated promising Phase 2 results for narcolepsy and is advancing into a pivotal Phase 3 program. Operating as a lean, virtual organization, NLS aims to efficiently navigate clinical development and address high-value market opportunities with limited treatment options.

Central Nervous System (CNS)Sleep-Wake Disorders

Technology Platform

Strategic drug repurposing and advanced formulation science focused on optimizing the pharmacokinetic and safety profiles of known molecules with validated mechanisms of action for CNS disorders.

Funding History

2
Total raised:$15M
PIPE$5M
IPO$10M

Opportunities

Mazindol ER's potential to treat both excessive daytime sleepiness and cataplexy in narcolepsy with a once-daily, non-amphetamine oral therapy addresses a major unmet need in a growing multi-billion dollar market.
Successful Phase 3 data could position the company as an attractive partner or acquisition target for larger CNS-focused pharma companies.

Risk Factors

The company faces high clinical risk as its value is concentrated in a single Phase 3 asset; trial failure would be catastrophic.
Financial risk is acute, with dependence on raising additional capital in volatile markets.
Regulatory risk includes potential drug scheduling and commercial risk from entrenched competitors.

Competitive Landscape

NLS competes in narcolepsy against dominant players like Jazz Pharmaceuticals (Xyrem/Xywav) and Harmony Biosciences (Wakix), as well as generic stimulants. Its differentiation hinges on Mazindol ER's dual-efficacy profile and historical non-controlled status, but it must overcome significant commercial and market access hurdles.

More companies in Switzerland →